Quote:
> Of course dah..ling, as you did in your supportive and positive
>{*filter*}-up with your *Peg OMG* lunacy
> Do you have any proof that PEG is safe? do you?
Once again Kims argument is that since there is not proof of ghosts,
there are ghosts.
Argument from ignorance.
Hoof
Hi Lynne,
Of course Im ignorant...and all these {*filter*} have been reviewed or pulled for no
reason, simply because there was a citizen or two concerned with ghosts.
ABBOKINASE
#1473 Letter to Dr. Jane Henney (FDA Commissioner) urging immediate recall of
Abbokinase, a widely-used clot-busting drug, because of possible contamination
with infectious agents (2/99) 10pp.
ACTIFED
#818A Letter to FDA condemning the illegal decision to classify Actifed tablets
and syrup (Burroughs Wellcome) as effective for the treatment of seasonal and
perennial allergic rhinitis. (2/82) 6pp.
ACCUTANE (isotretinoin)
#910 Petition urging the FDA to immediately warn patients and doctors about
serious, life-threatening and vision-threatening adverse reactions occurring in
young healthy people using Roche's drug, Accutane (isotretinoin), approved for
the treatment of severe cystic acne. (9/83) 12pp.
#964 Objections to a statement of Roche officials concerning Accutane and
disagreement with Advisory Committee recommendations based on these statements.
(7/84) 9pp.
#1123 Testimony before the Dermatologic Drug Advisory Committee Meeting on the
drug Accutane, which causes severe birth defects and is used to treat cystic
acne. HRG urges restrictions on the authority to prescribe, on labeling, and on
sales, and recommends the use of informed consent forms by all female patients.
(4/88) 21pp.
#1125 Petition to the Commissioner of the cooking.net">food and Drug Administration, and to
the Secretary of Health and Human Services, urging that the distribution of the
drug Accutane be limited, in order to avoid further unnecessary birth defects
and {*filter*}s. (5/88) 18pp.
#1166 Testimony before the cooking.net">food and Drug Administration Dermatologic {*filter*}
Advisory Committee Hearing on Accutane, recommending immediate restrictions to
reduce Accutane prescribing to severe acne, postmarketing surveillance with
100% follow-up, and supplying product warnings to physicians. (5/89) 9pp.
#1199 Statement before the FDA Joint Fertility & Maternal Health and
Dermatologic Drug Advisory Committees on Accutane. Includes charts comparing
Accutane use in the US and other countries. (5/90) 7pp.
#1537 Comments by Larry D. Sasich, Pharm.D., M.P.H, FASHP before the FDA's
Dermatologic and Ophthalmic {*filter*} Advisory Committee meeting on isotretinoin
(Accutane) (9/18/00)
ACNE - see ACCUTANE
ACTOS - see REZULIN
ADVERTISING - see PROMOTION, DRUG
AIDS/{*filter*} - See also AIDS under HEALTH CARE DELIVERY INDEX
#1137 Petition by HRG and the American Public Health Association to Dr. Bowen,
Secretary of Health and Human Services, requesting a change in its policies on
patenting and licensing of AIDS related {*filter*} and vaccines developed in U.S.
Government institutions or other federal research grants. (8/88) 11pp.
#1139 Letter to National Institutes of Health proposing incorporation of price
controls and rate of development in licensing agreements for the promising new
AIDS drug CD4-PE. (10/88) 4pp.
ALKA-SELTZER
#72 Report on aspirin in Alka-Seltzer as a cause of gastro-intestinal bleeding.
(4/73) 5pp.
ALUPENT
#897 Citizen's Petition urging the FDA to halt over-the-counter (OTC) sales of
metraproterenol sulfate metered dose inhalers (Alupent) in order to prevent
unnecessary asthma deaths. (5/83) 8pp.
AMPHETAMINE
#1131A Transcript of the Good Morning America Show on the Air Force and
Amphetamine/Sedative use. (7/88) 2pp.
ANIMAL EXPERIMENTATION - see HEALTH CARE DELIVERY INDEX
ANORECTICS - see ANTI-OBESITY {*filter*}
ANTIARTHRITICS - see brand names: BUTAZOLIDIN, FELDENE, ORAFLEX, etc.
ANTIBIOTICS
#993 Hearings in House Subcommittee on antibiotic misuse and antibiotic
resistance. (12/84) 6pp.
#1031 Letter to FDA regarding the international symposium on worldwide
antibiotic use which was delayed by drug companies. (9/85) 4pp.
#1440 Statement of Sidney M. Wolfe, MD, concerning the Center for Science in
the Public Interest report on threats to antibiotic effectiveness. (5/98) 3pp.
ANTI-DEPRESSANT/ANTI-PSYCHOTICS - see PRICING
ANTI-DIARRHEAL {*filter*}
#1283 Citizen's petition for a ban and/or relabeling of Antidiarrheal {*filter*}.
(1/93) 21pp.
#1288 Testimony of Sidney Wolfe, MD, and Peter Lurie, MD, before the FDA
Over-the-Counter Advisory Committee Meeting on Anti-Diarrheal {*filter*}. (4/93)
33pp.
ANTIHISTAMINES - see GUAIFENESIN and OTC {*filter*}
ANTIHYPERTENSIVES - see SELACRYN
ANTI-OBESITY {*filter*} - see also PHENYLPROPANOLAMINE and ORLISTAT
#743 Testimony before FDA on the anti-obesity {*filter*} phendimetrazine,
diethylpropion and phentermine, concerning Drug Enforcement Agency
recommendations for rescheduling them. (11/80) 8pp.
ANTIVERT
#1128 Letter to Frank Young, M.D., Commissioner of the cooking.net">food and Drug
Administration, requesting initiation of regulatory action to have Roerig, a
subdivision of Pfizer Pharmaceuticals, immediately withdraw their misleading
adverti{*filter*}t for Antivert as effective for vertigo. The adverti{*filter*}t depicts
an ironworker laboring on a pedestal high above the city, but cautions that
sleepiness is a possible side-effect. (6/88) 3pp.
APPROVAL PROCESS - see NEW DRUG APPROVAL PROCESS
ARLIDIN
#994 Letter asking FDA to remove Arlidin, an ineffective vasodilator, from the
market. (12/84) 14pp.
ARTHRITIS see BUTAZOLIDIN, FELDENE, ORAFLEX
ASPIRIN - see REYE'S SYNDROME and ALKA-SELTZER
ASTHMA - see ALUPENT
AVANDIA - see REZULIN
BENDECTIN
#781 Letter and petition to HHS requesting the removal of Bendectin from the
market because of lack of demonstrated effectiveness. (6/81) 12pp.
#843 Petition to HHS requesting that Bendectin and all other fixed-combination
{*filter*} containing doxylamine and pyridoxine be removed from the market because
of an animal study showing an increased risk of diaphragmatic hernia, a serious
birth defect. (6/82) l0pp.
#896 Petition urging FDA to immediately require a patient package insert (PPI)
for Bendectin, the prescription drug for morning sickness, warning women of the
risk of birth defects which may result from use of this drug. (5/83) 12pp.
#905 Letter to pharmacists concerning a letter from Merrell-Dow, the maker of
Bendectin, which is an attempt to bribe pharmacists to continue dispensing
Bendectin to pregnant women even though the manufacturer has ceased production
of the drug. (7/83) 4pp.
BENOXAPROFEN - see ORAFLEX
BENZODIAZEPINES - see DALMANE, HALCION, LIBRIUM, VALIUM
#778 Testimony before the Drug Abuse Advisory Committee Meeting recommending
that benzodiazepines be listed in the Schedules of the International Convention
on Psychotropic Substances. (5/81) 7pp.
#812 Letter urging HHS to ignore pressure from pharmaceutical firms attempting
to convince the U.S. not to support international controls for twelve dangerous
{*filter*}, all in the benzodiazepine family (Valium, Librium, Dalmane, etc.) (1/82)
6pp.
#1272A Letters to the Editor of JAMA on the regulation of benzodiazepine
prescription. (7/92) 3pp.
BIOTECHNOLOGY
#1467 Statement before FDA Science Forum on Biotechnology on threats to safe
and effective FDA regulation of products (12/98) 6 pp.
BIRTH CONTROL PILL -see also ESTROGENS; HORMONES, SEX
#543 Statement on reasons for decline in use of the birth control pill, citing
cancer studies. Includes chart on use patterns from l968 to l977. (5/78) 2pp.
#918 Letter urging FDA to warn American women and their doctors of two recent
studies showing a strong association between the birth control pill and {*filter*}
and cervical cancer. (11/83) 4pp.
#1116 Statement by Sidney Wolfe, M.D. to the FDA workshop on birth control
pills with an Estrogen content greater then 50 Micrograms, advocating that FDA
protect the health of women from the dangers of high dose estrogen pills by
banning their sale immediately. (1/88) 4pp.
#1153 Statement by Sidney M. Wolfe, M.D. on the need for immediate revision of
doctor and patient labeling for the birth control pill. (1/89) 2pp.
#1189 Petition to the FDA requesting a change in the labeling on {*filter*}
contraceptives to include a warning on the possible increased risk of {*filter*}
cancer. (2/90) 16pp.
BROMOCRIPTINE
#1126 Statement on Bromocriptine (Parlodel) to the FDA's Fertility and Maternal
and Child Health Advisory Committee, recommending that the indication of
Bromocriptine for lactation suppression in post-partum women be removed. (6/88)
5pp.
#1146 Petition to Frank Young, Commissioner of the cooking.net">food and Drug Administration
(FDA), urging FDA to ban the use of hormones and the drug Bromocriptine
(Parlodel) to stop milk production and {*filter*} engorgement in women electing not
to {*filter*}feed after giving birth. (11/89) 17pp.
#1158 Follow-up letter to Frank Young, Commissioner of the cooking.net">food and Drug
Administration, concerning our November petition calling for a halt to the use
of Bromocriptine for lactation suppression. We inform FDA of the large number
of leading obstetricians who support our petition. (3/89) 4pp.
#1169 Statement before the FDA Fertility and Maternal Health {*filter*} Advisory
Committee hearing on lactation suppressants (Bromocriptine). (6/89) 6pp.
#1170 Continuation of statement before the FDA Fertility and Maternal Health
{*filter*} Advisory Committee hearing on Bromocriptine. (6/89) 5pp.
#1309 Petition to FDA urging them to immediately take steps to ban the
prescription drug Bromocriptine for the treatment of postpartum {*filter*}
engorgement (PPBE). (9/93) 13pp.
#1346 Letter to Kessler, FDA Commissioner, concerning filing of Public
Citizen's Health Research Group and National Women's Health Network law suit in
the U.S. Court of Appeals for the District of Columbia to force the FDA to
begin the process of banning the drug parlodel for post-partum {*filter*}
...
read more »